Intellia Therapeutics (NASDAQ:NTLA) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $65.00 price target on the stock.

A number of other brokerages also recently issued reports on NTLA. Citigroup reduced their price target on Intellia Therapeutics from $31.00 to $29.00 and set a neutral rating on the stock in a research report on Friday, May 10th. Wedbush restated a neutral rating and set a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. BMO Capital Markets upped their target price on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an outperform rating in a research note on Friday, May 10th. Truist Financial restated a buy rating and set a $120.00 target price on shares of Intellia Therapeutics in a research note on Monday. Finally, StockNews.com upgraded Intellia Therapeutics to a sell rating in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $69.00.

Intellia Therapeutics Trading Up 1.2 %

Intellia Therapeutics stock opened at $23.19 on Monday. Intellia Therapeutics has a 12 month low of $19.37 and a 12 month high of $46.50. The stock’s 50 day moving average is $23.74 and its 200-day moving average is $26.36. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -4.33 and a beta of 1.84.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The business had revenue of $28.94 million for the quarter, compared to the consensus estimate of $15.60 million. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. As a group, equities research analysts predict that Intellia Therapeutics will post -4.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Avidity Partners Management LP increased its holdings in Intellia Therapeutics by 18.0% in the fourth quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock valued at $13,642,000 after purchasing an additional 68,334 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Intellia Therapeutics by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after purchasing an additional 18,987 shares during the period. ARK Investment Management LLC increased its holdings in Intellia Therapeutics by 14.7% in the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after purchasing an additional 1,463,820 shares during the period. American Century Companies Inc. increased its holdings in Intellia Therapeutics by 5.9% in the third quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock valued at $8,449,000 after purchasing an additional 14,863 shares during the period. Finally, Raymond James Financial Services Advisors Inc. increased its holdings in Intellia Therapeutics by 13.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock valued at $1,104,000 after purchasing an additional 4,255 shares during the period. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.